Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.1 Million EUR | 51.22% |
| 2022 | -12.19 Million EUR | 55.49% |
| 2021 | -27.38 Million EUR | -101.43% |
| 2020 | -13.59 Million EUR | 61.13% |
| 2019 | -34.97 Million EUR | 10.08% |
| 2018 | -38.89 Million EUR | -78.35% |
| 2017 | -21.8 Million EUR | 53.48% |
| 2016 | -46.87 Million EUR | 52.89% |
| 2015 | -99.5 Million EUR | -265.54% |
| 2014 | -27.22 Million EUR | -43.63% |
| 2013 | -18.95 Million EUR | -2518.97% |
| 2012 | -723.63 Thousand EUR | -722.45% |
| 2011 | 116.25 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.07 Million EUR | 0.0% |
| 2023 FY | 10.68 Million EUR | 187.65% |
| 2023 Q4 | -6.1 Million EUR | 0.0% |
| 2023 Q2 | -4.44 Million EUR | 0.0% |
| 2022 Q1 | -18.11 Million EUR | 33.85% |
| 2022 Q4 | 4.44 Million EUR | 0.0% |
| 2022 FY | -12.19 Million EUR | 55.49% |
| 2022 Q2 | -12.22 Million EUR | 32.54% |
| 2021 Q4 | -27.38 Million EUR | -747.6% |
| 2021 Q2 | -8.93 Million EUR | -2.31% |
| 2021 Q1 | -8.73 Million EUR | 35.76% |
| 2021 FY | -27.38 Million EUR | -101.43% |
| 2021 Q3 | -3.23 Million EUR | 63.84% |
| 2020 Q4 | -13.59 Million EUR | 0.0% |
| 2020 Q2 | -22.98 Million EUR | 0.0% |
| 2020 FY | -13.59 Million EUR | 61.13% |
| 2019 Q4 | -34.97 Million EUR | 0.0% |
| 2019 Q2 | -28.73 Million EUR | 0.0% |
| 2019 FY | -34.97 Million EUR | 10.08% |
| 2018 Q4 | -38.89 Million EUR | 0.0% |
| 2018 FY | -38.89 Million EUR | -78.35% |
| 2018 Q2 | -61.08 Million EUR | 0.0% |
| 2017 FY | -21.8 Million EUR | 53.48% |
| 2017 Q2 | -22.25 Million EUR | 0.0% |
| 2017 Q4 | -21.8 Million EUR | 0.0% |
| 2016 FY | -46.87 Million EUR | 52.89% |
| 2016 Q4 | -46.87 Million EUR | 0.0% |
| 2016 Q2 | -51.95 Million EUR | 0.0% |
| 2015 FY | -99.5 Million EUR | -265.54% |
| 2015 Q2 | -115.61 Million EUR | 0.0% |
| 2015 Q4 | -99.5 Million EUR | 0.0% |
| 2014 FY | -27.22 Million EUR | -43.63% |
| 2014 Q2 | -34.75 Million EUR | 0.0% |
| 2014 Q4 | -27.22 Million EUR | 0.0% |
| 2013 Q4 | -18.95 Million EUR | 0.0% |
| 2013 Q2 | -3.77 Million EUR | 0.0% |
| 2013 FY | -18.95 Million EUR | -2518.97% |
| 2012 Q4 | -723.63 Thousand EUR | 0.0% |
| 2012 FY | -723.63 Thousand EUR | -722.45% |
| 2011 FY | 116.25 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -754.622% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 96.894% |
| Adocia SA | 127 Thousand EUR | 4904.724% |
| Aelis Farma SA | -16.19 Million EUR | 62.315% |
| Biophytis S.A. | 2.7 Million EUR | 325.749% |
| Advicenne S.A. | 12.17 Million EUR | 150.119% |
| genOway Société anonyme | 2.97 Million EUR | 305.249% |
| IntegraGen SA | -709.74 Thousand EUR | -759.741% |
| Medesis Pharma S.A. | 1.15 Million EUR | 626.847% |
| Neovacs S.A. | -237.08 Thousand EUR | -2473.739% |
| NFL Biosciences SA | -2.27 Million EUR | -168.117% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 240.066% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -634.696% |
| Sensorion SA | 1.37 Million EUR | 542.744% |
| Theranexus Société Anonyme | 2.44 Million EUR | 349.657% |
| TME Pharma N.V. | -1.07 Million EUR | -465.524% |
| Valbiotis SA | -18.13 Million EUR | 66.36% |
| TheraVet SA | 12.78 Thousand EUR | 47827.806% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 379.908% |
| argenx SE | -1.83 Billion EUR | 99.668% |
| BioSenic S.A. | 28.04 Million EUR | 121.759% |
| DBV Technologies S.A. | -114.95 Million USD | 94.692% |
| Galapagos NV | -157.2 Million EUR | 96.118% |
| Genfit S.A. | -7.61 Million EUR | 19.827% |
| GeNeuro SA | 5.91 Million EUR | 203.242% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 75.701% |
| Innate Pharma S.A. | -30.71 Million EUR | 80.132% |
| Inventiva S.A. | 10.48 Million EUR | 158.175% |
| MaaT Pharma SA | -10.2 Million EUR | 40.206% |
| MedinCell S.A. | 39.5 Million EUR | 115.448% |
| Nanobiotix S.A. | -24.71 Million EUR | 75.314% |
| Onward Medical N.V. | -12.89 Million EUR | 52.676% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 526.614% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 122.493% |
| Oxurion NV | 10.71 Million EUR | 156.975% |
| Pharming Group N.V. | 99.4 Million EUR | 106.139% |
| Poxel S.A. | 44.55 Million EUR | 113.694% |
| GenSight Biologics S.A. | 16.29 Million EUR | 137.449% |
| Transgene SA | -14.4 Million EUR | 57.651% |
| Financière de Tubize SA | 78.62 Million EUR | 107.761% |
| UCB SA | 2.17 Billion EUR | 100.28% |
| Valneva SE | 82.73 Million EUR | 107.375% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 67.059% |